Klebsiella pneumoniae BY PCR

Klebsiella pneumoniae BY PCR is a molecular at‑home diagnostic test that detects Klebsiella pneumoniae DNA in clinical specimens using real‑time polymerase chain reaction (PCR). The assay reports qualitative presence/absence of the organism, provides cycle‑threshold (Ct) values as a semi‑quantitative indicator of bacterial load, and may include detection of common resistance markers to inform clinical decisions. Rapid and sensitive, this test supports early diagnosis, targeted treatment, and prompt infection‑control actions in community and healthcare settings across Dubai, UAE.

This PCR test is useful for patients with suspected respiratory or urinary infections, unexplained fever, or for screening colonization in high‑risk individuals and contacts during outbreak investigations. A positive PCR result helps clinicians accelerate appropriate antibiotic therapy and can prompt confirmatory culture and susceptibility testing when required; negative results can help rule out K. pneumoniae as the cause of symptoms. As with all molecular diagnostics, results should be reviewed by a healthcare professional in the context of clinical findings and local antimicrobial stewardship guidelines in the UAE.

• Klebsiella pneumoniae DNA (qualitative)
• Cycle threshold (Ct) value — semi‑quantitative bacterial load indicator
• Carbapenemase/β‑lactamase resistance markers (e.g., blaKPC, blaNDM, blaOXA‑48) where included
• Internal control for sample adequacy and assay validity

• Patients with suspected pneumonia or lower respiratory tract infection
• Signs of urinary tract infection with severe or persistent symptoms
• Unexplained sepsis or bacteremia where Gram‑negative infection is suspected
• Screening contacts or patients during suspected healthcare‑associated outbreaks
• Pre‑admission or pre‑procedure screening in high‑risk patients or facilities

• Rapid, high‑sensitivity detection of K. pneumoniae to guide timely therapy
• At‑home sample collection for patient convenience across Dubai
• Identification of key resistance markers to support targeted antibiotic choices
• Supports infection‑control and public‑health response for outbreaks
• Laboratory‑validated results to be reviewed by treating clinicians

• Appropriate clinical sample: sputum or tracheal aspirate for respiratory infection, midstream urine for UTI, or rectal/nares swab for colonization screening
• For sputum: early morning deep cough specimen preferred; for urine: clean‑catch midstream sample
• Patient must provide valid Emirates ID and informed consent for at‑home collection
• Be available for the scheduled home collection; samples should be transported promptly under recommended conditions for accurate results